Treatment of gustatory hyperlacrimation (crocodile tears) with injection of botulinum toxin into the lacrimal gland
Eye (2002) 16, 705–709. doi: 10.1038/sj.eye.6700230
Presented as a poster at the Royal College of Ophthalmologists Congress 2000. The authors received no funding for this work
F J Montoya1, C E Riddell1, R Caesar1 and S Hague1
1Oxford Eye Hospital Radcliffe Infirmary Oxford, UK
Correspondence: S Hague, Oxford Eye Hospital Woodstock Road Oxford OX2 6HE, UK Tel: ++44 (0)1865 311188 Fax: ++44 (0) 1865 224013 E-mail: Jean.Butler@orh.nhs.uk
Received 19 December 2000; Accepted 18 May 2001.
Top of pageAbstract
Purpose To establish the efficacy and safety of botulinum toxin in the treatment of Crocodile Tear Syndrome and record any possible complications.
Methods Four patients with unilateral aberrant VII cranial nerve regeneration following an episode of facial paralysis consented to be included in this study after a comprehensive explanation of the procedure and possible complications was given. On average, an injection of 20 units of botulinum toxin type A (Dysport®) was given to the affected lacrimal gland. The effect was assessed with a Schirmer’s test during taste stimulation. Careful recording of the duration of the effect and the presence of any local or systemic complications was made.
Results All patients reported a partial or complete disappearance of the reflex hyperlacrimation following treatment. Schirmer’s tests during taste stimulation documented a significant decrease in tear secretion. The onset of effect of the botulinum toxin was typically 24–48 h after the initial injection and lasted 4–5 months. One patient had a mild increase in his preexisting upper lid ptosis, but no other local or systemic side effects were experienced.
Conclusions The injection of botulinum toxin type A into the affected lacrimal glands of patients with gusto-lacrimal reflex is a simple, effective and safe treatment.
Presented as a poster at the Royal College of Ophthalmologists Congress 2000. The authors received no funding for this work
F J Montoya1, C E Riddell1, R Caesar1 and S Hague1
1Oxford Eye Hospital Radcliffe Infirmary Oxford, UK
Correspondence: S Hague, Oxford Eye Hospital Woodstock Road Oxford OX2 6HE, UK Tel: ++44 (0)1865 311188 Fax: ++44 (0) 1865 224013 E-mail: Jean.Butler@orh.nhs.uk
Received 19 December 2000; Accepted 18 May 2001.
Top of pageAbstract
Purpose To establish the efficacy and safety of botulinum toxin in the treatment of Crocodile Tear Syndrome and record any possible complications.
Methods Four patients with unilateral aberrant VII cranial nerve regeneration following an episode of facial paralysis consented to be included in this study after a comprehensive explanation of the procedure and possible complications was given. On average, an injection of 20 units of botulinum toxin type A (Dysport®) was given to the affected lacrimal gland. The effect was assessed with a Schirmer’s test during taste stimulation. Careful recording of the duration of the effect and the presence of any local or systemic complications was made.
Results All patients reported a partial or complete disappearance of the reflex hyperlacrimation following treatment. Schirmer’s tests during taste stimulation documented a significant decrease in tear secretion. The onset of effect of the botulinum toxin was typically 24–48 h after the initial injection and lasted 4–5 months. One patient had a mild increase in his preexisting upper lid ptosis, but no other local or systemic side effects were experienced.
Conclusions The injection of botulinum toxin type A into the affected lacrimal glands of patients with gusto-lacrimal reflex is a simple, effective and safe treatment.
留言
張貼留言